The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and ...
Health and Me on MSN
The early warning signs of chronic kidney disease you shouldn't ignore
As India becomes the second-largest population of people living with chronic kidney disease globally, the nation faces a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results